المؤلفون: Albertson, Timothy E, Bowman, Willis S, Harper, Richart W, Godbout, Regina M, Murin, Susan

مصطلحات موضوعية: Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Lung, Chronic Obstructive Pulmonary Disease, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Respiratory, Administration, Inhalation, Adrenergic beta-2 Receptor Agonists, Benzyl Alcohols, Bronchodilator Agents, Chlorobenzenes, Drug Combinations, Dry Powder Inhalers, Evidence-Based Medicine, Humans, Muscarinic Antagonists, Pulmonary Disease, Chronic Obstructive, Quinuclidines, Recovery of Function, Treatment Outcome, fixed-dose combination inhalers, long-acting beta(2)-adrenergic agonists, LABA, long-acting muscarinic antagonists, LAMA, COPD, umeclidinium bromide, vilanterol trifenatate, long-acting beta2-adrenergic agonists, Cardiorespiratory Medicine and Haematology, Respiratory System, Cardiovascular medicine and haematology

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/0gm2429fTest

المؤلفون: Elena V. Bolotova, Anna V. Dudnikova, Larisa V. Shulzhenko

المصدر: Терапевтический архив, Vol 94, Iss 3, Pp 396-400 (2022)

مصطلحات موضوعية: chronic obstructive pulmonary disease, eosinophilia, frequency of exacerbations, triple fixed combination, vilanterol/umeclidinium bromide/fluticasone furoate, Medicine

وصف الملف: electronic resource

العلاقة: https://ter-arkhiv.ru/0040-3660/article/viewFile/80734/pdfTest; https://doaj.org/toc/0040-3660Test; https://doaj.org/toc/2309-5342Test

الوصول الحر: https://doaj.org/article/00c05ee1dc064092969efb27b6ac81f4Test

المؤلفون: A. I. Sinopalnikov

المصدر: Медицинский совет, Vol 0, Iss 16, Pp 38-44 (2021)

مصطلحات موضوعية: bronchodilators, fixed combinations, long-acting beta2-agonists, long-acting cholinoblockers, umeclidinium bromide/vilanterol, Medicine

وصف الملف: electronic resource

العلاقة: https://www.med-sovet.pro/jour/article/view/6458Test; https://doaj.org/toc/2079-701XTest; https://doaj.org/toc/2658-5790Test

الوصول الحر: https://doaj.org/article/a62fc5ded4c84a1fa00d0b6466426625Test

المؤلفون: E. V. Bolotova, A. V. Dudnikova, L. V. Shulzhenko

المصدر: Медицинский совет, Vol 0, Iss 16, Pp 10-16 (2021)

مصطلحات موضوعية: chronic respiratory diseases, long-term therapy, fixed-dose drug combination, vilanterol/umeclidinium bromide/fluticasone furoate, treatment adherence, Medicine

وصف الملف: electronic resource

العلاقة: https://www.med-sovet.pro/jour/article/view/6454Test; https://doaj.org/toc/2079-701XTest; https://doaj.org/toc/2658-5790Test

الوصول الحر: https://doaj.org/article/f3b3ea603ebd473081ef181c066f819dTest

المؤلفون: Albertson TE, Bowman WS, Harper RW, Godbout RM, Murin S

المصدر: International Journal of COPD, Vol Volume 14, Pp 1251-1265 (2019)

مصطلحات موضوعية: Fixed-dose combination inhalers, long-acting beta2-adrenergic agonists (LABA), long-acting muscarinic antagonists (LAMA), COPD, umeclidinium bromide, vilanterol trifenatate, Diseases of the respiratory system, RC705-779

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/evidence-based-review-of-data-on-the-combination-inhaler-umeclidiniumv-peer-reviewed-article-COPDTest; https://doaj.org/toc/1178-2005Test

الوصول الحر: https://doaj.org/article/e57e6b3f54ef45fdbeaa4ad4ea6e9939Test

المؤلفون: E N Popova

المصدر: Терапевтический архив, Vol 87, Iss 12, Pp 107-110 (2015)

مصطلحات موضوعية: chronic obstructive pulmonary disease, umeclidinium bromide, vilanterol, anoro ellipta, Medicine

وصف الملف: electronic resource

العلاقة: https://ter-arkhiv.ru/0040-3660/article/view/31891Test; https://doaj.org/toc/0040-3660Test; https://doaj.org/toc/2309-5342Test

الوصول الحر: https://doaj.org/article/1b675da5b5b84bd7a5136186e198f0c4Test

المؤلفون: S. Yu. Chikina, С. Ю. Чикина

المصدر: PULMONOLOGIYA; Том 26, № 1 (2016); 79-84 ; Пульмонология; Том 26, № 1 (2016); 79-84 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2016-26-1

مصطلحات موضوعية: легочная функция, vilanterol, umeclidinium bromide, chronic obstructive pulmonary disease, dyspnea, quality of life, lung function, вилантерол, умеклидиния бромид, хроническая обструктивная болезнь легких, одышка, качество жизни

وصف الملف: application/pdf

العلاقة: https://journal.pulmonology.ru/pulm/article/view/676/598Test; Cazzola M., Molimard M. The scientific rationale for combining long acting beta2 agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 2010; 23 (4): 257–267.; Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2015. http://www.goldcopd.org/uploads/users/filesTest/ GOLD_Report_2013_Feb20.pdf; Coleman C.I., Limone B., Sobieraj D.M. et al. Dosing frequency and medication adherence in chronic disease. J. Manag. Care Pharm. 2012; 18 (7): 527–539.; Decramer M., Anzueto A., Kerwin E. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir. Med. 2014; 2 (6): 472–486.; Celli B., Crater G., Kilbride S. et al. Once daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014; 145 (5): 981–991.; Donohue J.F., Maleki Yazdi M.R., Kilbride S. et al. Efficacy and safety of once daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir. Med. 2013; 107 (10): 1538–1546.; Cazzola M., MacNee W., Martinez F.J. et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31 (2): 416–469.; O'Donnell D.E., Lam M., Webb K.A. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 158 (5, Pt 1): 1557–1565.; Maltais F., Singh S., Donald A.C. et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double blind clinical trials. Ther. Adv. Respir. Dis. 2014; 8 (6): 169–181.; Maleki Yazdi M.R., Kaelin T., Richard N. et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24 week, randomized, controlled trial. Respir. Med. 2014; 108 (12): 1752–1760.; Svedsater H., Jacques L., Goldfrad C., Bleecker E.R. Ease of use of the Ellipta dry powder inhaler: data from three randomized controlled trials in patients with asthma. Primary Care Respir. Med. 2014; 24: 14019. doi:10.1038/npjpcrm. 2014.19; Svedsater H., Dale P., Garrill K. et al. Qualitative assessment of attributes and ease of use of the ELLIPTATM dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm. Med. 2013; 13: 72. doi:10.1186/1471 2466 13 72.; https://journal.pulmonology.ru/pulm/article/view/676Test

الإتاحة: https://doi.org/10.18093/0869-0189-2016-26-1-79-84Test
https://doi.org/10.18093/0869-0189-2016-26-1Test
https://doi.org/10.1038/npjpcrmTest
https://doi.org/10.1186/1471Test
https://journal.pulmonology.ru/pulm/article/view/676Test

المؤلفون: Maria Gabriella Matera, Beatrice Ludovica Ritondo, Luigino Calzetta, Josuel Ora, Paola Rogliani

المساهمون: Ora, J., Calzetta, L., Ritondo, B. L., Matera, M. G., Rogliani, P.

مصطلحات موضوعية: Adrenergic beta-2 Receptor Agonist, Muscarinic Antagonists, Pharmacology, Umeclidinium bromide, Adrenal Cortex Hormone, umeclidinium bromide, law.invention, glycopyrronium bromide, Pulmonary Disease, Chronic Obstructive, Randomized controlled trial, law, Adrenal Cortex Hormones, Muscarinic acetylcholine receptor, Administration, Inhalation, medicine, tiotropium bromide, Settore MED/10, Humans, Pharmacology (medical), Glycopyrronium bromide, Adrenergic beta-2 Receptor Agonists, Bronchodilator Agent, Asthma, biology, business.industry, LAMA, General Medicine, Tiotropium bromide, Lama, asthma, medicine.disease, biology.organism_classification, Bronchodilator Agents, Long-acting muscarinic antagonist, Muscarinic Antagonist, Long acting, triple therapy, business, Human, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71d1c7892306d19b4645e3ef22c34c55Test
http://hdl.handle.net/2108/285632Test

المؤلفون: Ora J., Calzetta L., Ritondo B. L., Matera M. G., Rogliani P.

المساهمون: Ora, J, Calzetta, L, Ritondo, Bl, Matera, Mg, Rogliani, P

مصطلحات موضوعية: LAMA, Long-acting muscarinic antagonist, asthma, glycopyrronium bromide, tiotropium bromide, triple therapy, umeclidinium bromide, Administration, Inhalation, Adrenal Cortex Hormones, Adrenergic beta-2 Receptor Agonists, Bronchodilator Agents, Humans, Muscarinic Antagonists, Pulmonary Disease, Chronic Obstructive, Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34219573; info:eu-repo/semantics/altIdentifier/wos/WOS:000673854600001; volume:22; issue:17; firstpage:2343; lastpage:2357; numberofpages:15; journal:EXPERT OPINION ON PHARMACOTHERAPY; http://hdl.handle.net/2108/285632Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85110930953

الإتاحة: https://doi.org/10.1080/14656566.2021.1952182Test
http://hdl.handle.net/2108/285632Test

المؤلفون: Tim Baker, Dhvani Shah, Afisi S. Ismaila, Maurice Driessen, Ian Naya, Andrew Briggs, Nancy Risebrough

المصدر: Respiratory Medicine. 145:130-137

مصطلحات موضوعية: Male, Pulmonary and Respiratory Medicine, Quinuclidines, medicine.medical_specialty, Exacerbation, Cost effectiveness, Cost-Benefit Analysis, Muscarinic Antagonists, Umeclidinium bromide, Maintenance Chemotherapy, Pulmonary Disease, Chronic Obstructive, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Humans, 030212 general & internal medicine, Adrenergic beta-2 Receptor Agonists, health care economics and organizations, COPD, biology, business.industry, Middle Aged, Lama, biology.organism_classification, medicine.disease, Androstadienes, Treatment Outcome, 030228 respiratory system, chemistry, Delayed-Action Preparations, Ics laba, Disease Progression, Fluticasone, Drug Therapy, Combination, Female, Vilanterol, Salmeterol, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4978f1d3f949d56965475446dce97174Test
https://doi.org/10.1016/j.rmed.2018.10.024Test